DD 01
Alternative Names: DD-01 - D and D Pharmatech; DD01Latest Information Update: 05 Feb 2025
Price :
$50 *
At a glance
- Originator D and D Pharmatech
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I Obesity; Type 2 diabetes mellitus
Most Recent Events
- 03 Feb 2025 D and D Pharmatech completes enrolment in a phase II trial in Non-alcoholic steatohepatitis in USA (SC) (NCT06410924)
- 13 Jun 2024 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (SC) (NCT06410924)
- 15 May 2024 Neuraly plans a phase II trial for Non alcoholic steatohepatitis (In adults, In the elderly) in the US (SC) (NCT06410924)